{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:05:29Z","timestamp":1789290329976,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001790","name":"Central Queensland University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00794-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:49:20Z","timestamp":1782395360000},"page":"801-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8203-923X","authenticated-orcid":false,"given":"Rebecca J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-4602","authenticated-orcid":false,"given":"Charmaine A.","family":"Ramlogan-Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-9759","authenticated-orcid":false,"given":"William J.","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0723-4530","authenticated-orcid":false,"given":"Sarah J.","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-9991","authenticated-orcid":false,"given":"Christopher J.","family":"Layton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-7542","authenticated-orcid":false,"given":"Jason C.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"794_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93\u2013102. https:\/\/doi.org\/10.4103\/0301-4738.154367.","journal-title":"Indian J Ophthalmol"},{"key":"794_CR2","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/cncr.29727","volume":"122","author":"C Chattopahdyay","year":"2016","unstructured":"Chattopahdyay C, Kim DW, Gombos D, Oba J, Qin Y, Williams M, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122:2299\u2013312. https:\/\/doi.org\/10.1002\/cncr.29727.","journal-title":"Cancer"},{"key":"794_CR3","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.3390\/cancers13235894","volume":"13","author":"M Chalada","year":"2021","unstructured":"Chalada M, Ramlogan-Steel CA, Dhungel BP, Goh AY, Gardiner S, Layton CJ, et al. Differences in uveal melanoma age-standardized incidence rates in two eastern states of Australia are driven by differences in rurality and ultraviolet radiation. Cancers (Basel). 2021;13:5894. https:\/\/doi.org\/10.3390\/cancers13235894.","journal-title":"Cancers (Basel)."},{"key":"794_CR4","doi-asserted-by":"publisher","unstructured":"Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83:1664\u201378. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19981015)83:8%3C1664::aid-cncr23%3E3.0.co;2-g.","DOI":"10.1002\/(sici)1097-0142(19981015)83:8%3C1664::aid-cncr23%3E3.0.co;2-g"},{"key":"794_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31:241\u201357. https:\/\/doi.org\/10.1038\/eye.2016.275.","journal-title":"Eye"},{"key":"794_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaapos.2011.10.012","volume":"16","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J Pediatr Ophthalmol Strabismus. 2012;16:10\u20136. https:\/\/doi.org\/10.1016\/j.jaapos.2011.10.012.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"794_CR7","first-page":"360","volume":"8","author":"M Costache","year":"2013","unstructured":"Costache M, Patrascu OM, Adrian D, Costache D, Sajin M, Ungureanu E, et al. Ciliary body melanoma: a particularly rare type of ocular tumor. Case report and general considerations. Maedica (Bucur). 2013;8:360\u20134.","journal-title":"Maedica (Bucur)."},{"key":"794_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","volume":"119","author":"EM Damato","year":"2012","unstructured":"Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology. 2012;119:1582\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.01.048.","journal-title":"Ophthalmology"},{"key":"794_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/bjophthalmol-2021-319700","volume":"107","author":"AB Beasley","year":"2023","unstructured":"Beasley AB, Preen DB, McLenachan S, Gray ES, Chen FK. Incidence and mortality of uveal melanoma in Australia (1982\u20132014). Br J Ophthalmol. 2023;107:406\u201311. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319700.","journal-title":"Br J Ophthalmol"},{"key":"794_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ijc.20690","volume":"114","author":"A Stang","year":"2005","unstructured":"Stang A, Parkin DM, Ferlay J, J\u00f6ckel K-H. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int J Cancer. 2005;114:114\u201323. https:\/\/doi.org\/10.1002\/ijc.20690.","journal-title":"Int J Cancer"},{"key":"794_CR11","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","volume":"114","author":"G Virgili","year":"2007","unstructured":"Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309-15.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.032.","journal-title":"Ophthalmology"},{"key":"794_CR12","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1167\/iovs.15-16532","volume":"56","author":"SJ Park","year":"2015","unstructured":"Park SJ, Oh C-M, Kim BW, Woo SJ, Cho H, Park KH. Nationwide incidence of ocular melanoma in South Korea by using the National Cancer Registry Database (1999\u20132011). Invest Ophthalmol Vis Sci. 2015;56:4719\u201324. https:\/\/doi.org\/10.1167\/iovs.15-16532.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"794_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","volume":"457","author":"CD Van Raamsdonk","year":"2009","unstructured":"Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O\u2019Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi. Nature. 2009;457:599\u2013602. https:\/\/doi.org\/10.1038\/nature07586.","journal-title":"Nature"},{"key":"794_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1000584.","journal-title":"N Engl J Med"},{"key":"794_CR15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133. https:\/\/doi.org\/10.1126\/science.1194472.","journal-title":"Science"},{"key":"794_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204-220.e15. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.003.","journal-title":"Cancer Cell"},{"key":"794_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern M-H, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6:24. https:\/\/doi.org\/10.1038\/s41572-020-0158-0.","journal-title":"Nat Rev Dis Primers"},{"key":"794_CR18","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.3390\/curroncol30070470","volume":"30","author":"L Banou","year":"2023","unstructured":"Banou L, Tsani Z, Arvanitogiannis K, Pavlaki M, Dastiridou A, Androudi S. Radiotherapy in uveal melanoma: a review of ocular complications. Curr Oncol. 2023;30:6374\u201396. https:\/\/doi.org\/10.3390\/curroncol30070470.","journal-title":"Curr Oncol"},{"key":"794_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38\u201344. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034.","journal-title":"Br J Ophthalmol"},{"key":"794_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639h21","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639\u201343. https:\/\/doi.org\/10.1001\/archopht.123.12.1639h21.","journal-title":"Arch Ophthalmol"},{"key":"794_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","volume":"160","author":"VT Gill","year":"2023","unstructured":"Gill VT, Norrman E, Sabazade S, Karim A, Lardner E, St\u00e5lhammar G. Multiorgan involvement of dormant uveal melanoma micrometastases in postmortem tissue from patients without coexisting macrometastases. Am J Clin Pathol. 2023;160:164\u201374. https:\/\/doi.org\/10.1093\/ajcp\/aqad029.","journal-title":"Am J Clin Pathol"},{"key":"794_CR22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","volume":"107","author":"S Eskelin","year":"2000","unstructured":"Eskelin S, Pyrh\u00f6nen S, Summanen P, Hahka-Kemppinen M, Kivel\u00e4 T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107:1443\u20139. https:\/\/doi.org\/10.1016\/S0161-6420(00)00182-2.","journal-title":"Ophthalmology"},{"key":"794_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivel\u00e4 TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000575.","journal-title":"Melanoma Res"},{"key":"794_CR24","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258.","journal-title":"Cancer"},{"key":"794_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","volume":"22","author":"A Rowcroft","year":"2020","unstructured":"Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22:497\u2013505. https:\/\/doi.org\/10.1016\/j.hpb.2019.11.002.","journal-title":"HPB (Oxford)"},{"key":"794_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18240\/ijo.2023.02.18","volume":"16","author":"Y-X Tao","year":"2023","unstructured":"Tao Y-X, Li H-W, Luo J-T, Li Y, Wei W-B. Regional chemotherapy for uveal melanoma liver metastases. Int J Ophthalmol. 2023;16:293\u2013300. https:\/\/doi.org\/10.18240\/ijo.2023.02.18.","journal-title":"Int J Ophthalmol"},{"key":"794_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/curroncol31020058","volume":"31","author":"KJ Synoradzki","year":"2024","unstructured":"Synoradzki KJ, Paduszy\u0144ska N, Solnik M, Toro MD, Bilmin K, Bylina E, et al. From molecular biology to novel immunotherapies and nanomedicine in uveal melanoma. Curr Oncol. 2024;31:778\u2013800. https:\/\/doi.org\/10.3390\/curroncol31020058.","journal-title":"Curr Oncol"},{"key":"794_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70425","volume":"8","author":"A Azani","year":"2025","unstructured":"Azani A, Ghassemifar V, Mehrdad Z, Saberivand M, Bagheripour A, Tahmasebi S, et al. Toward precision medicine: gene therapy applications in the management of uveal melanoma. Cancer Rep (Hoboken). 2025;8:e70425. https:\/\/doi.org\/10.1002\/cnr2.70425.","journal-title":"Cancer Rep (Hoboken)."},{"key":"794_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2021.1898587","volume":"30","author":"C Masaoutis","year":"2021","unstructured":"Masaoutis C, Kokkali S, Theocharis S. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert Opin Investig Drugs. 2021;30:555\u201369. https:\/\/doi.org\/10.1080\/13543784.2021.1898587.","journal-title":"Expert Opin Investig Drugs"},{"key":"794_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Amaral T, K\u00e4hler KC, Heinzerling L, Hassel JC, Meissner M, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7:299. https:\/\/doi.org\/10.1186\/s40425-019-0800-0.","journal-title":"J Immunother Cancer"},{"key":"794_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cancers11070971","volume":"11","author":"BE Damato","year":"2019","unstructured":"Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019;11:971. https:\/\/doi.org\/10.3390\/cancers11070971.","journal-title":"Cancers (Basel)."},{"key":"794_CR32","doi-asserted-by":"publisher","first-page":"175883592311601","DOI":"10.1177\/17588359231160140","volume":"15","author":"S Howlett","year":"2023","unstructured":"Howlett S, Carter TJ, Shaw HM, Nathan PD. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Ther Adv Med Oncol. 2023;15:17588359231160140. https:\/\/doi.org\/10.1177\/17588359231160140.","journal-title":"Ther Adv Med Oncol."},{"key":"794_CR33","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"key":"794_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181464","volume":"135","author":"R Staeger","year":"2025","unstructured":"Staeger R, Tastanova A, Ghosh A, Winkelbeiner N, Shukla P, Kolm I, et al. Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients. J Clin Invest. 2025;135:e181464. https:\/\/doi.org\/10.1172\/JCI181464.","journal-title":"J Clin Invest"},{"key":"794_CR35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","volume":"22","author":"LN Chen","year":"2022","unstructured":"Chen LN, Carvajal RD. Tebentafusp for the treatment of HLA-A*02:01\u2013positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev Anticancer Ther. 2022;22:1017\u201327. https:\/\/doi.org\/10.1080\/14737140.2022.2124971.","journal-title":"Expert Rev Anticancer Ther"},{"key":"794_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of Ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS ONE. 2015;10:e0118564. https:\/\/doi.org\/10.1371\/journal.pone.0118564.","journal-title":"PLoS ONE"},{"key":"794_CR37","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377.","journal-title":"J Clin Oncol"},{"key":"794_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/biomedicines13010108","volume":"13","author":"M Kulbay","year":"2025","unstructured":"Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E, et al. Oncolytic viruses and immunotherapy for the treatment of uveal melanoma and retinoblastoma: the current landscape and novel advances. Biomedicines. 2025;13:108. https:\/\/doi.org\/10.3390\/biomedicines13010108.","journal-title":"Biomedicines."},{"key":"794_CR39","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.3390\/jcm14145137","volume":"14","author":"M Grigoruta","year":"2025","unstructured":"Grigoruta M, Kong X, Qin Y. Advances and challenges in immunotherapy for metastatic uveal melanoma: clinical strategies and emerging targets. J Clin Med. 2025;14:5137. https:\/\/doi.org\/10.3390\/jcm14145137.","journal-title":"J Clin Med"},{"key":"794_CR40","doi-asserted-by":"publisher","first-page":"1555842","DOI":"10.3389\/fonc.2025.1555842","volume":"15","author":"AH Al Sharie","year":"2025","unstructured":"Al Sharie AH, Al-Omari SO, Aleshawi A, Al-Dwairi R, Al DO. Checkmate awaiting strategy: unlocking the potential of chimeric antigen receptor T-cell therapy in uveal melanoma. Front Oncol. 2025;15:1555842. https:\/\/doi.org\/10.3389\/fonc.2025.1555842.","journal-title":"Front Oncol"},{"key":"794_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.ccr-14-27080","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-27080.","journal-title":"Clin Cancer Res"},{"key":"794_CR42","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/jco.2017.74.5463","volume":"35","author":"Y-C Lu","year":"2017","unstructured":"Lu Y-C, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol. 2017;35:3322\u20139. https:\/\/doi.org\/10.1200\/jco.2017.74.5463.","journal-title":"J Clin Oncol"},{"key":"794_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0603","author":"J Moser","year":"2025","unstructured":"Moser J, Amaria RN, Warner AB, Chmielowski B, Fecher LA, Chandrasekaran S, et al. 603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator\u2019s choice in previously treated advanced cutaneous melanoma. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0603.","journal-title":"J Immunother Cancer"},{"key":"794_CR44","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.molonc.2015.10.006","volume":"9","author":"T Karpanen","year":"2015","unstructured":"Karpanen T, Olweus J. T-cell receptor gene therapy: ready to go viral? Mol Oncol. 2015;9:2019\u201342. https:\/\/doi.org\/10.1016\/j.molonc.2015.10.006.","journal-title":"Mol Oncol"},{"key":"794_CR45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/cancers14051215","volume":"14","author":"SB Strobel","year":"2022","unstructured":"Strobel SB, Machiraju D, Hassel JC. TCR-directed therapy in the treatment of metastatic uveal melanoma. Cancers (Basel). 2022;14:1215. https:\/\/doi.org\/10.3390\/cancers14051215.","journal-title":"Cancers (Basel)."},{"key":"794_CR46","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Foppen MHG, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387:2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"key":"794_CR47","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumor infiltrating lymphocytes: a single-center phase 2 study. Lancet Oncol. 2017;18:792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"Lancet Oncol"},{"key":"794_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fmed.2018.00150","volume":"5","author":"RK Iyer","year":"2018","unstructured":"Iyer RK, Bowles PA, Kim H, Dulgar-Tulloch A. Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Front Med (Lausanne). 2018;5:150. https:\/\/doi.org\/10.3389\/fmed.2018.00150.","journal-title":"Front Med (Lausanne)."},{"key":"794_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201020","volume":"33","author":"TF McCall","year":"2025","unstructured":"McCall TF, Sawyer EJ, Darnell J, Hirsch ML, Bower JJ. Allele-specific depletion of GNAQQ209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQQ209L uveal melanoma cells. Mol Ther Oncol. 2025;33:201020. https:\/\/doi.org\/10.1016\/j.omton.2025.201020.","journal-title":"Mol Ther Oncol."},{"key":"794_CR50","doi-asserted-by":"publisher","first-page":"368","DOI":"10.7150\/jca.9147","volume":"5","author":"A Sakkas","year":"2014","unstructured":"Sakkas A, Zarogoulidis P, Domvri K, Hohenforst-Schmidt W, Bougiouklis D, Kakolyris S, et al. Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines. J Cancer. 2014;5:368\u201381. https:\/\/doi.org\/10.7150\/jca.9147.","journal-title":"J Cancer"},{"key":"794_CR51","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1167\/iovs.02-1147","volume":"44","author":"H Alizadeh","year":"2003","unstructured":"Alizadeh H, Howard K, Mellon J, Mayhew E, Rusciano D, Niederkorn JY. Reduction of liver metastasis of intraocular melanoma by interferon-\u03b2 gene transfer. Invest Ophthalmol Vis Sci. 2003;44:3042\u201351. https:\/\/doi.org\/10.1167\/iovs.02-1147.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"794_CR52","first-page":"S1131","volume":"37","author":"R Rota","year":"1996","unstructured":"Rota R, Cirielli C, Blasi MA, Martinotti S, Toniato E, Capogrossi M, et al. Adenovirus-mediated wild-type p53 gene transfer induces apoptosis and inhibits proliferation of human uveal melanoma cells. Invest Ophthalmol Vis Sci. 1996;37:S1131.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"794_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.exer.2018.04.009","volume":"172","author":"S Liu","year":"2018","unstructured":"Liu S, Song W, Liu F, Zhang J, Zhu S. Antitumor efficacy of VP22-CD\/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model. Exp Eye Res. 2018;172:144\u201351. https:\/\/doi.org\/10.1016\/j.exer.2018.04.009.","journal-title":"Exp Eye Res"},{"key":"794_CR54","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","volume":"33","author":"NR Hackett","year":"2025","unstructured":"Hackett NR, Crystal RG. Four decades of adenovirus gene transfer vectors: history and current use. Mol Ther. 2025;33:2192\u2013204. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.062.","journal-title":"Mol Ther"},{"key":"794_CR55","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/v16060973","volume":"16","author":"R Wallace","year":"2024","unstructured":"Wallace R, Bliss CM, Parker AL. The immune system: a double-edged sword for adenovirus-based therapies. Viruses. 2024;16:973. https:\/\/doi.org\/10.3390\/v16060973.","journal-title":"Viruses"},{"key":"794_CR56","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529\u201341. https:\/\/doi.org\/10.1038\/s41375-018-0106-0.","journal-title":"Leukemia"},{"key":"794_CR57","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/v13081528","volume":"13","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021;13:1528. https:\/\/doi.org\/10.3390\/v13081528.","journal-title":"Viruses"},{"key":"794_CR58","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022009087","volume":"7","author":"S Radtke","year":"2023","unstructured":"Radtke S, Pande D, Enstrom M, Kiem H-P. Safe and efficient lentiviral vector integration with HSC-targeted gene therapy. Blood Adv. 2023;7:5132\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2022009087.","journal-title":"Blood Adv"},{"key":"794_CR59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","volume":"28","author":"FD Bushman","year":"2020","unstructured":"Bushman FD. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones. Mol Ther. 2020;28:352\u20136. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.009.","journal-title":"Mol Ther"},{"key":"794_CR60","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.gendis.2022.03.007","volume":"10","author":"L Deng","year":"2022","unstructured":"Deng L, Liang P, Cui H. Pseudotyped lentiviral vectors: ready for translation into targeted cancer gene therapy? Genes Dis. 2022;10:1937\u201355. https:\/\/doi.org\/10.1016\/j.gendis.2022.03.007.","journal-title":"Genes Dis."},{"key":"794_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/asia.202500684","volume":"20","author":"F Wang","year":"2025","unstructured":"Wang F, Liang L, Wang C, Zhang C, Ye Y, Dou L, et al. Non-viral gene delivery systems: current advances and therapeutic applications. Chem Asian J. 2025;20:e00684. https:\/\/doi.org\/10.1002\/asia.202500684.","journal-title":"Chem Asian J"},{"key":"794_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","volume":"23","author":"H Zu","year":"2021","unstructured":"Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23:78. https:\/\/doi.org\/10.1208\/s12248-021-00608-7.","journal-title":"AAPS J"},{"key":"794_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125470","volume":"674","author":"S Honrath","year":"2025","unstructured":"Honrath S, Burger M, Leroux J-C. Hurdles to healing: overcoming cellular barriers for viral and nonviral gene therapy. Int J Pharm. 2025;674:125470. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125470.","journal-title":"Int J Pharm"},{"key":"794_CR64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1208\/s12249-025-03184-7","volume":"26","author":"R Bhawale","year":"2025","unstructured":"Bhawale R, Khan O, Vasave R, Yadav R, Mehra NK. Nanotechnology in uveal melanoma: cutting-edge advances to halt progression and metastasis. AAPS PharmSciTech. 2025;26:191. https:\/\/doi.org\/10.1208\/s12249-025-03184-7.","journal-title":"AAPS PharmSciTech"},{"key":"794_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.109983","volume":"245","author":"R Maurya","year":"2024","unstructured":"Maurya R, Vikal A, Narang RK, Patel P, Kurmi BD. Recent advancements and applications of ophthalmic gene therapy strategies: a breakthrough in ocular therapeutics. Exp Eye Res. 2024;245:109983. https:\/\/doi.org\/10.1016\/j.exer.2024.109983.","journal-title":"Exp Eye Res"},{"key":"794_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","journal-title":"Signal Transduct Target Ther"},{"key":"794_CR67","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, Ragni MV, Rasko JEJ, Raffini LJ, Samelson-Jones BJ, Ozelo M, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28:2073\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001.","journal-title":"Mol Ther"},{"key":"794_CR68","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14712598.2022.2121646","volume":"22","author":"KD Kovacs","year":"2022","unstructured":"Kovacs KD, Ciulla TA, Kiss S. Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques. Expert Opin Biol Ther. 2022;22:1193\u2013208. https:\/\/doi.org\/10.1080\/14712598.2022.2121646.","journal-title":"Expert Opin Biol Ther"},{"key":"794_CR69","doi-asserted-by":"publisher","first-page":"1310050","DOI":"10.3389\/fmed.2023.1310050","volume":"10","author":"X Xia","year":"2023","unstructured":"Xia X, Guo X. Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies. Front Med (Lausanne). 2023;10:1310050. https:\/\/doi.org\/10.3389\/fmed.2023.1310050.","journal-title":"Front Med (Lausanne)."},{"key":"794_CR70","doi-asserted-by":"publisher","first-page":"1750807","DOI":"10.3389\/fmolb.2025.1750807","volume":"12","author":"X Xu","year":"2026","unstructured":"Xu X. Strategies of AAV capsid engineering for targeted delivery to brain, muscle, and retina. Front Mol Biosci. 2026;12:1750807. https:\/\/doi.org\/10.3389\/fmolb.2025.1750807.","journal-title":"Front Mol Biosci"},{"key":"794_CR71","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"794_CR72","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20:173\u20134. https:\/\/doi.org\/10.1038\/d41573-021-00017-7.","journal-title":"Nat Rev Drug Discov"},{"key":"794_CR73","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1128\/jvi.63.9.3822-3828.1989","volume":"63","author":"RJ Samulski","year":"1989","unstructured":"Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 1989;63:3822\u20138. https:\/\/doi.org\/10.1128\/jvi.63.9.3822-3828.1989.","journal-title":"J Virol"},{"key":"794_CR74","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","volume":"75","author":"H Nakai","year":"2001","unstructured":"Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75:6969\u201376. https:\/\/doi.org\/10.1128\/JVI.75.15.6969-6976.2001.","journal-title":"J Virol"},{"key":"794_CR75","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/ceo.13416","volume":"47","author":"CA Ramlogan-Steel","year":"2019","unstructured":"Ramlogan-Steel CA, Murali A, Andrzejewski S, Dhungel B, Steel JC, Layton CJ. Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations. Clin Exp Ophthalmol. 2019;47:521\u201336. https:\/\/doi.org\/10.1111\/ceo.13416.","journal-title":"Clin Exp Ophthalmol"},{"key":"794_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","volume":"38","author":"BFM Castro","year":"2024","unstructured":"Castro BFM, Steel JC, Layton CJ. AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies. BioDrugs. 2024;38:73\u201393. https:\/\/doi.org\/10.1007\/s40259-023-00629-y.","journal-title":"BioDrugs"},{"key":"794_CR77","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.4","volume":"26","author":"B Castro","year":"2024","unstructured":"Castro B, Steel JC, Layton CJ. AAV-mediated gene therapies for glaucoma and uveitis: are we there yet? Expert Rev Mol Med. 2024;26:e9. https:\/\/doi.org\/10.1017\/erm.2024.4.","journal-title":"Expert Rev Mol Med"},{"key":"794_CR78","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","volume":"36","author":"V Kansara","year":"2020","unstructured":"Kansara V, Muya L, Wan C, Ciulla TA. Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther. 2020;36:384\u201392. https:\/\/doi.org\/10.1089\/jop.2019.0126.","journal-title":"J Ocul Pharmacol Ther"},{"key":"794_CR79","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/v16030442","volume":"16","author":"E Lopez-Gordo","year":"2024","unstructured":"Lopez-Gordo E, Chamberlain K, Riyad JM, Kohlbrenner E, Weber T. Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights. Viruses. 2024;16:442. https:\/\/doi.org\/10.3390\/v16030442.","journal-title":"Viruses"},{"key":"794_CR80","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3390\/cancers11070979","volume":"11","author":"NJ Brouwer","year":"2019","unstructured":"Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, et al. Tumour angiogenesis in uveal melanoma is related to genetic evolution. Cancers (Basel). 2019;11:979. https:\/\/doi.org\/10.3390\/cancers11070979.","journal-title":"Cancers (Basel)."},{"key":"794_CR81","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.21037\/atm-20-4417","volume":"9","author":"SH Chung","year":"2021","unstructured":"Chung SH, Frick SL, Yiu G. Targeting vascular endothelial growth factor using retinal gene therapy. Ann Transl Med. 2021;9:1277. https:\/\/doi.org\/10.21037\/atm-20-4417.","journal-title":"Ann Transl Med."},{"key":"794_CR82","doi-asserted-by":"publisher","first-page":"9831","DOI":"10.1128\/JVI.00878-06","volume":"80","author":"B Akache","year":"2006","unstructured":"Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37\/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006;80:9831\u20136. https:\/\/doi.org\/10.1128\/JVI.00878-06.","journal-title":"J Virol"},{"key":"794_CR83","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/sj.bjc.6601374","volume":"89","author":"W Zuidervaart","year":"2003","unstructured":"Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJJ, Singh AD, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer. 2003;89:1914\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6601374.","journal-title":"Br J Cancer"},{"key":"794_CR84","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/pharmaceutics14081523","volume":"14","author":"S-C Hsu","year":"2022","unstructured":"Hsu S-C, Wu N-P, Lu Y-C, Ma Y-H. Laminin receptor-mediated nanoparticle uptake by tumor cells: interplay of epigallocatechin gallate and magnetic force at nano\u2013bio interface. Pharmaceutics. 2022;14:1523. https:\/\/doi.org\/10.3390\/pharmaceutics14081523.","journal-title":"Pharmaceutics"},{"key":"794_CR85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/mt.2009.199","volume":"18","author":"J Scheiman","year":"2010","unstructured":"Scheiman J, Tseng J-C, Zheng Y, Meruelo D. Multiple functions of the 37\/67-kd laminin receptor make It a suitable target for novel cancer gene therapy. Mol Ther. 2010;18:63\u201374. https:\/\/doi.org\/10.1038\/mt.2009.199.","journal-title":"Mol Ther"},{"key":"794_CR86","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.molonc.2013.08.003","volume":"7","author":"J Liu","year":"2013","unstructured":"Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W. Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Mol Oncol. 2013;7:1043\u201355. https:\/\/doi.org\/10.1016\/j.molonc.2013.08.003.","journal-title":"Mol Oncol"},{"key":"794_CR87","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41587-022-01224-2","volume":"40","author":"K North","year":"2022","unstructured":"North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol. 2022;40:1103\u201313. https:\/\/doi.org\/10.1038\/s41587-022-01224-2.","journal-title":"Nat Biotechnol"},{"key":"794_CR88","first-page":"1994","volume":"43","author":"K Mori","year":"2002","unstructured":"Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1994\u20132000.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"794_CR89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/gt.2011.151","volume":"19","author":"LH Vandenberghe","year":"2012","unstructured":"Vandenberghe LH, Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther. 2012;19:162\u20138. https:\/\/doi.org\/10.1038\/gt.2011.151.","journal-title":"Gene Ther"},{"key":"794_CR90","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41434-020-0162-8","volume":"28","author":"S Andrzejewski","year":"2021","unstructured":"Andrzejewski S, Moyle PM, Stringer BW, Steel JC, Layton CJ. Neutralisation of adeno-associated virus transduction by human vitreous humour. Gene Ther. 2021;28:242\u201355. https:\/\/doi.org\/10.1038\/s41434-020-0162-8.","journal-title":"Gene Ther"},{"key":"794_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2021","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors: implications for treatment success and safety. Prog Retin Eye Res. 2021;83:100915. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100915.","journal-title":"Prog Retin Eye Res"},{"key":"794_CR92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.31083\/j.fbl2702072","volume":"27","author":"S Ka\u0161telan","year":"2022","unstructured":"Ka\u0161telan S, Zimak DM, Ivankovi\u0107 M, Markovi\u0107 I, Antunica AG. Liver metastasis in uveal melanoma: treatment options and clinical outcome. Front Biosci (Landmark Ed). 2022;27:72. https:\/\/doi.org\/10.31083\/j.fbl2702072.","journal-title":"Front Biosci (Landmark Ed)."},{"key":"794_CR93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287\u2013301. https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.001.","journal-title":"J Control Release"},{"key":"794_CR94","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1006\/mthe.2001.0345","volume":"3","author":"M Grifman","year":"2001","unstructured":"Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 2001;3:964\u201375. https:\/\/doi.org\/10.1006\/mthe.2001.0345.","journal-title":"Mol Ther"},{"key":"794_CR95","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3892\/ol.2011.376","volume":"2","author":"HS Lee","year":"2011","unstructured":"Lee HS, Kim JY, Lee WI, Kim SJ, Ko MJ, Jeong S, et al. Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins. Oncol Lett. 2011;2:1113\u20139. https:\/\/doi.org\/10.3892\/ol.2011.376.","journal-title":"Oncol Lett"},{"key":"794_CR96","doi-asserted-by":"publisher","first-page":"1566584","DOI":"10.3389\/fonc.2025.1566584","volume":"15","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Ji W, Zhang Q, Dong Y, Liu L. Adeno-associated virus vector modification based on directed evolution technology for gene therapy targeting head and neck squamous cell carcinoma. Front Oncol. 2025;15:1566584. https:\/\/doi.org\/10.3389\/fonc.2025.1566584.","journal-title":"Front Oncol"},{"key":"794_CR97","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.1038\/ncomms7246","volume":"6","author":"RC M\u00fcnch","year":"2015","unstructured":"M\u00fcnch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, et al. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun. 2015;6:6246. https:\/\/doi.org\/10.1038\/ncomms7246.","journal-title":"Nat Commun"},{"key":"794_CR98","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445\u201351. https:\/\/doi.org\/10.1038\/nrg3742.","journal-title":"Nat Rev Genet"},{"key":"794_CR99","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","volume":"28","author":"C Domenger","year":"2019","unstructured":"Domenger C, Grimm D. Next-generation AAV vectors: do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28:R3-14. https:\/\/doi.org\/10.1093\/hmg\/ddz148.","journal-title":"Hum Mol Genet"},{"key":"794_CR100","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.1128\/jvi.77.20.11072-11081.2003","volume":"77","author":"A Kern","year":"2003","unstructured":"Kern A, Schmidt K, Leder C, M\u00fcller OJ, Wobus CE, Bettinger K, et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol. 2003;77:11072\u201381. https:\/\/doi.org\/10.1128\/jvi.77.20.11072-11081.2003.","journal-title":"J Virol"},{"key":"794_CR101","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/10717544.2016.1247926","volume":"24","author":"B Dhungel","year":"2017","unstructured":"Dhungel B, Jayachandran A, Layton CJ, Steel JC. Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. Drug Deliv. 2017;24:289\u201399. https:\/\/doi.org\/10.1080\/10717544.2016.1247926.","journal-title":"Drug Deliv"},{"key":"794_CR102","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.1038\/s41598-018-33801-4","volume":"8","author":"B Dhungel","year":"2018","unstructured":"Dhungel B, Ramlogan-Steel CA, Steel JC. Synergistic and independent action of endogenous microRNAs 122a and 199a for post-transcriptional liver detargeting of gene vectors. Sci Rep. 2018;8:15539. https:\/\/doi.org\/10.1038\/s41598-018-33801-4.","journal-title":"Sci Rep"},{"key":"794_CR103","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41434-018-0002-2","volume":"25","author":"B Dhungel","year":"2018","unstructured":"Dhungel B, Andrzejewski S, Jayachandran A, Shrestha R, Ramlogan-Steel CA, Layton CJ, et al. Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma. Gene Ther. 2018;25:115\u201328. https:\/\/doi.org\/10.1038\/s41434-018-0002-2.","journal-title":"Gene Ther"},{"key":"794_CR104","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/104303402753812511","volume":"13","author":"P\u00d8 Enger","year":"2002","unstructured":"Enger P\u00d8, Thorsen F, L\u00f8nning PE, Bjerkvig R, Hoover F. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Ther. 2002;13:1115\u201325. https:\/\/doi.org\/10.1089\/104303402753812511.","journal-title":"Hum Gene Ther"},{"key":"794_CR105","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","volume":"381","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, et al. Tyrosine phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology. 2008;381:194\u2013202. https:\/\/doi.org\/10.1016\/j.virol.2008.08.027.","journal-title":"Virology"},{"key":"794_CR106","doi-asserted-by":"publisher","first-page":"13035","DOI":"10.1128\/JVI.01826-13","volume":"87","author":"AM Mitchell","year":"2013","unstructured":"Mitchell AM, Samulski RJ. Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. J Virol. 2013;87:13035\u201341. https:\/\/doi.org\/10.1128\/JVI.01826-13.","journal-title":"J Virol"},{"key":"794_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803. https:\/\/doi.org\/10.3389\/fimmu.2022.975803.","journal-title":"Front Immunol"},{"key":"794_CR108","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186\u201391. https:\/\/doi.org\/10.1038\/nature14299.","journal-title":"Nature"},{"key":"794_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/rr6","volume":"1","author":"TR Flotte","year":"2000","unstructured":"Flotte TR. Size does matter: overcoming the adeno-associated virus packaging limit. Respir Res. 2000;1:16\u20138. https:\/\/doi.org\/10.1186\/rr6.","journal-title":"Respir Res"},{"key":"794_CR110","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/gt.2010.87","volume":"17","author":"M Watanabe","year":"2010","unstructured":"Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 2010;17:1042\u201351. https:\/\/doi.org\/10.1038\/gt.2010.87.","journal-title":"Gene Ther"},{"key":"794_CR111","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh4456","volume":"13","author":"B Angelici","year":"2021","unstructured":"Angelici B, Shen L, Schreiber J, Abraham A, Benenson Y. An AAV gene therapy computes over multiple cellular inputs to enable precise targeting of multifocal hepatocellular carcinoma in mice. Sci Transl Med. 2021;13:eabh4456. https:\/\/doi.org\/10.1126\/scitranslmed.abh4456.","journal-title":"Sci Transl Med"},{"key":"794_CR112","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1038\/s41467-020-19314-7","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Huang W, Cai Z. Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells. Nat Commun. 2020;11:5486. https:\/\/doi.org\/10.1038\/s41467-020-19314-7.","journal-title":"Nat Commun"},{"key":"794_CR113","doi-asserted-by":"publisher","first-page":"0291","DOI":"10.34133\/research.0291","volume":"6","author":"X He","year":"2023","unstructured":"He X, Fu Y, Ma L, Yao Y, Ge S, Yang Z, et al. AAV for gene therapy in ocular diseases: progress and prospects. Research (Wash D C). 2023;6:0291. https:\/\/doi.org\/10.34133\/research.0291.","journal-title":"Research (Wash D C)."},{"issue":"3","key":"794_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101545","volume":"33","author":"M Ferrand","year":"2025","unstructured":"Ferrand M, Rocca CJ, Corre G, Buffa V, Frin S, Garnache-Ottou F, et al. FAP-CAR-T cells reduce dystrophic muscle fibrosis, improving adeno-associated virus gene transfer efficacy. Mol Ther Methods Clin Dev. 2025;33(3):101545. https:\/\/doi.org\/10.1016\/j.omtm.2025.101545.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"794_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.64.15.36","volume":"64","author":"MC Gelmi","year":"2023","unstructured":"Gelmi MC, Gezgin G, van der Velden PA, Luyten GPM, Luk SJ, Heemskerk MHM, et al. PRAME expression: a target for cancer immunotherapy and a prognostic factor in uveal melanoma. Invest Ophthalmol Vis Sci. 2023;64:36. https:\/\/doi.org\/10.1167\/iovs.64.15.36.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"794_CR116","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-24-0071","volume":"30","author":"M Ventin","year":"2024","unstructured":"Ventin M, Cattaneo G, Arya S, Jia J, Gelmi MC, Sun Y, et al. Chimeric antigen receptor T cell with an inducible caspase-9 suicide gene eradicates uveal melanoma liver metastases via B7-H3 targeting. Clin Cancer Res. 2024;30:3243\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0071.","journal-title":"Clin Cancer Res"},{"key":"794_CR117","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41434-019-0076-5","volume":"26","author":"S Andrzejewski","year":"2019","unstructured":"Andrzejewski S, Murali A, Ramlogan-Steel C, Edwards KP, Efron N, Steel JC, et al. Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus. Gene Ther. 2019;26:250\u201363. https:\/\/doi.org\/10.1038\/s41434-019-0076-5.","journal-title":"Gene Ther"},{"key":"794_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664968","volume":"16","author":"Y Ma","year":"2025","unstructured":"Ma Y, Shen Y. Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies. Front Immunol. 2025;16:1664968. https:\/\/doi.org\/10.3389\/fimmu.2025.1664968.","journal-title":"Front Immunol"},{"key":"794_CR119","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455\u201364. https:\/\/doi.org\/10.1056\/NEJMra1706910.","journal-title":"N Engl J Med"},{"key":"794_CR120","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf130","volume":"112","author":"A Huibers","year":"2025","unstructured":"Huibers A, Wong A, Burgmans M, Ny L, St\u00e5lhammar G, Kapiteijn E, et al. Management of liver metastases from uveal melanoma. Br J Surg. 2025;112:znaf130. https:\/\/doi.org\/10.1093\/bjs\/znaf130.","journal-title":"Br J Surg"},{"key":"794_CR121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605.","journal-title":"J Clin Oncol"},{"key":"794_CR122","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carri\u00f3n L, Mart\u00edn-Algarra S, et al. Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39:586\u201398. https:\/\/doi.org\/10.1200\/JCO.20.00550.","journal-title":"J Clin Oncol"},{"key":"794_CR123","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"key":"794_CR124","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garc\u00eda","year":"2019","unstructured":"Garc\u00eda M, Moreno R, Gil-Martin M, Cascall\u00f2 M, de Olza MO, Cuadra C, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30:352\u201364. https:\/\/doi.org\/10.1089\/hum.2018.107.","journal-title":"Hum Gene Ther"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00794-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:02:40Z","timestamp":1789290160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00794-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"3 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christopher J. Layton is the founder of Ocugene, a preclinical, pre-revenue gene therapy company developing AAV-based therapies for ocular disease. Jason C. Steel has served as a consultant for Ocugene. Christopher J. Layton and Jason C. Steel are inventors on issued and pending patents in Australia and the USA relating to AAV and adenoviral vector technologies. Rebecca J. Wilson, Charmaine A. Ramlogan-Steel, William J. Deasy and Sarah J. Greenstein have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analysed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation: RJW, JCS; writing, review and editing: RJW, JCS, CAR-S, WJD, CJL, SJG; visualisation: RJW, JCS, SJG; project administration: JCS, CAR-S. All authors have read and agreed to the published version of the manuscript. All content, scientific ideas and conclusions remain the sole responsibility of the authors, who have thoroughly reviewed and edited the entire manuscript. Figures were created with BioRender (\n                      \n                      ) [Accessed 19 Jan 2026].","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}